MedTrace Logo

A Safety Study of Hylan GF-20 to Treat Shoulder Osteoarthritis

NCT00253799 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2007-06-25

No results posted yet for this study

Summary

The objective is to assess the safety and efficacy (over the course of 26 weeks) of 2 intra-articular (IA) Hylan GF-20 (Synvisc) injections in addition to customary care in patients with painful glenohumeral osteoarthritis.

Conditions

  • Painful Shoulder Osteoarthritis

Interventions

DEVICE

Hylan GF-20

Sponsors & Collaborators

  • Northwestern Ophthalmic Institute S.C.

    lead OTHER

Principal Investigators

  • Victoria A Brander, MD · Northwestern Ophthalmic Institute S.C.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00253799 on ClinicalTrials.gov